Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Srikanta Dash,1– 3 Yucel Aydin,1 Kyle E Widmer,2 Leela Nayak2 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA; 2Southeast Louisiana Veterans Health Care System, New Orleans, LA 70119, USA; 3Department of Medicine, Divis...

Full description

Bibliographic Details
Main Authors:	Dash S, Aydin Y, Widmer KE, Nayak L
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-04-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	hepatitis c virus (hcv) hepatocellular carcinoma (hcc) interferon (ifn) direct-acting antiviral (daa) endoplasmic reticulum stress (er stress) autophagy
Online Access:	https://www.dovepress.com/hepatocellular-carcinoma-mechanisms-associated-with-chronic-hcv-infect-peer-reviewed-article-JHC

Similar Items

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
by: Tom Domovitz, et al.
Published: (2021-02-01)

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals
by: Devis Pascut, et al.
Published: (2019-11-01)

Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response
by: Srikanta Dash, et al.
Published: (2016-05-01)

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
by: Chen-Ta Chi, et al.
Published: (2021-06-01)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
by: Stefania Brozzetti, et al.
Published: (2021-06-01)

Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals
by: Dimitrios N. Samonakis, et al.
Published: (2021-03-01)

Evaluation of direct-acting antivirals and antiretroviral therapy for HIV-HCV coinfected patients in the United States
by: Rivera, Josef Kyle Concepcion
Published: (2021)

Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020-01-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
by: Julia L. Casey, et al.
Published: (2019-04-01)

LONG TERM FOLLOW UP AFTER HCV CURE WITH DIRECT ACTING ANTIVIRALS – REVIEW OF THE LITERATURE
by: Andreea Ruxandra Cazan, et al.
Published: (2018-12-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals
by: Ahmed Mohamed ElGhandour, et al.
Published: (2021-01-01)

Chaperone-Mediated Autophagy in the Liver:<br /> Good or Bad?
by: Srikanta Dash, et al.
Published: (2019-10-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2021-12-01)

Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment
by: Elisa Biliotti, et al.
Published: (2021-11-01)

Extracellular Vesicle Release Promotes Viral Replication during Persistent HCV Infection
by: Yucel Aydin, et al.
Published: (2021-04-01)

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
by: Elton Dajti, et al.
Published: (2021-06-01)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
by: Stefania Paolucci, et al.
Published: (2020-02-01)

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
by: Bernuth S, et al.
Published: (2017-07-01)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
by: Luca Rinaldi, et al.
Published: (2020-05-01)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
by: Gao X, et al.
Published: (2020-12-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma
by: Maria Lucia De Luca, et al.
Published: (2019-08-01)

Genotypic resistance testing of HCV – is there a clinical need?
by: Walker, Andreas, et al.
Published: (2016-08-01)

Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C–Related Advanced Fibrosis and Cirrhosis
by: Kilany S, et al.
Published: (2021-08-01)

Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection
by: Jinyuan Wei, et al.
Published: (2020-06-01)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
by: Huan Xia, et al.
Published: (2020-05-01)

Intracellular Accumulation of IFN-λ4 Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects
by: Olusegun O. Onabajo, et al.
Published: (2021-08-01)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
by: Hye Won Lee, et al.
Published: (2020-11-01)

ER-Phagy and Its Role in ER Homeostasis in Plants
by: Yan Bao, et al.
Published: (2020-12-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)